Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.77 |
| ▸ | KIT | P10721 | 5/20 | 0.61 |
| ▸ | FLT3 | P36888 | 5/20 | 0.61 |
| ▸ | ABL1 | P00519 | 11/20 | 0.56 |
| ▸ | BCR | P11274 | 9/20 | 0.56 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | FLT1 | P17948 | 3/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | FLT4 | P35916 | 2/20 | 0.54 |
| ▸ | BLK | P51451 | 2/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28760140 | 0.90 | KDR (0.62) | KDRKITFLT3ABL1BCR | |
| SCHEMBL27636382 | 0.89 | KDR (0.60) | KDRKITFLT3ABL1BCR | |
| SCHEMBL29923459 | 0.87 | KDR (1.00) | KDRKITFLT3ABL1BCR | |
| SCHEMBL1426417 | 0.87 | KDR (1.00) | KDRKITFLT3ABL1BCR | |
| SCHEMBL4784983 | 0.87 | KDR (0.62) | KDRKITFLT3ABL1BCR | |
| SCHEMBL27657284 | 0.86 | KDR (0.57) | KDRKITFLT3ABL1BCR | |
| SCHEMBL4739159 | 0.86 | KDR (0.78) | KDRKITFLT3ABL1BCR | |
| Water SCHEMBL15475146 | 0.86 | KDR (0.98) | KDRKITFLT3ABL1BCR | |
| SCHEMBL27657344 | 0.86 | KDR (0.69) | KDRKITFLT3ABL1BCR | |
| SCHEMBL4737713 | 0.85 | KDR (0.77) | KDRKITFLT3ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1826324-B | indazole, Benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-12-07 | — | — | CN | claimed |
| CN-1826324-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2006-08-30 | — | — | CN | claimed |
| CN-1826324-B | indazole, Benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-12-07 | — | — | CN | disclosed |
| CN-101827584-A | Solid dispersion product of N-aryl ureido drugs | ABBOTT GMBH & CO KG | 2010-09-08 | — | — | CN | disclosed |
| WO-2008080110-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | ALCON, INC. (CH) | 2008-07-03 | — | — | WO | disclosed |
| CN-1826324-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | KDR 800/4885KIT 238/4885FLT3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.